Fosaprepitant is an antiemetic drug used in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting caused by chemotherapy. It is a prodrug of Aprepitant.
- Mechanism
- Curator reviewed
Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with Aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that Aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid ethasone and inhibits both the acute and delayed phases of cisplatin induced emesis. In summary, the active form of fosaprepitant is as an NK1 antagonist which is because it blocks signals given off by NK1 receptors. This therefore decreases the likelihood of vomiting in patients experiencing.
- Primary indication
- Fosaprepitant is indicated in adult and pediatric patients ≥6 months of age, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of...Curator reviewed · 3 structured indications
- Formula / weight
- C23H22F7N4O6P · 614.4066 g/mol (avg)
- First approval
- Canada, 2009 · United States, 2008 · European Union, 2016
- Code names
- L-758,298
- Brand names
Resolves to
BARDROPHSZEBKC-OITMNORJSA-NSMILESC[C@@H](O[C@H]1OCCN(CC2=NC(=O)N(N2)P(O)(O)=O)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)FWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Fosaprepitant, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account